{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:47:21Z","timestamp":1790365641663,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Several studies suggest that harnessing natural killer (NK) cell reactivity mediated through killer cell immunoglobulin-like receptors (KIRs) could reduce the risk of relapse after allogeneic hematopoietic cell transplantation. Based on one promising model, information on KIR2DS1 and KIR3DL1 and their cognate ligands can be used to classify donors as KIR-advantageous or KIR-disadvantageous. This study was aimed at externally validating this model in unrelated donor hematopoietic cell transplantation. The impact of the predictor on overall survival (OS) and relapse incidence was tested in a Cox regression model adjusted for patient age, a modified disease risk index, Karnofsky performance status, donor age, HLA match, sex match, cytomegalovirus match, conditioning intensity, type of T-cell depletion, and graft type. Data from 2222 patients with acute myeloid leukemia or myelodysplastic syndrome were analyzed. KIR genes were typed by using high-resolution amplicon-based next-generation sequencing. In univariable analyses and subgroup analyses, OS and the cumulative incidence of relapse of patients with a KIR-advantageous donor were comparable to patients with a KIR-disadvantageous donor. The adjusted hazard ratio from the multivariable Cox regression model was 0.99 (Wald test, P = .93) for OS and 1.04 (Wald test, P = .78) for relapse incidence. We also tested the impact of activating donor KIR2DS1 and inhibition by KIR3DL1 separately but found no significant impact on OS and the risk of relapse. Thus, our study shows that the proposed model does not universally predict NK-mediated disease control. Deeper knowledge of NK-mediated alloreactivity is necessary to predict its contribution to graft-versus-leukemia reactions and to eventually use KIR genotype information for donor selection.<\/jats:p>","DOI":"10.1182\/blood.2019002887","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T03:59:28Z","timestamp":1578974368000},"page":"1386-1395","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["External validation of models for KIR2DS1\/KIR3DL1-informed selection of hematopoietic cell donors fails"],"prefix":"10.1182","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2780-2981","authenticated-orcid":false,"given":"Johannes","family":"Schetelig","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany;"},{"name":"DKMS gemeinn\u00fctzige GmbH, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Baldauf","sequence":"first","affiliation":[{"name":"DKMS gemeinn\u00fctzige GmbH, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Heidenreich","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany;"},{"name":"DKMS gemeinn\u00fctzige GmbH, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Massalski","sequence":"first","affiliation":[{"name":"DKMS Life Science Laboratory, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Frank","sequence":"first","affiliation":[{"name":"Deutsches Register f\u00fcr Stammzelltransplantationen e.V., Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-2945","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Sauter","sequence":"first","affiliation":[{"name":"DKMS gemeinn\u00fctzige GmbH, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"first","affiliation":[{"name":"Universit\u00e4tsklinikum M\u00fcnster, M\u00fcnster, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Ayuketang","family":"Ayuk","sequence":"first","affiliation":[{"name":"Universit\u00e4tsklinikum Hamburg Eppendorf, Hamburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Bethge","sequence":"first","affiliation":[{"name":"Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gesine","family":"Bug","sequence":"first","affiliation":[{"name":"Universit\u00e4tsklinikum Frankfurt, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Klein","sequence":"first","affiliation":[{"name":"Universit\u00e4tsmedizin Mannheim, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wendler","sequence":"first","affiliation":[{"name":"DKMS gemeinn\u00fctzige GmbH, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6442-9573","authenticated-orcid":false,"given":"Vinzenz","family":"Lange","sequence":"first","affiliation":[{"name":"DKMS Life Science Laboratory, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth C.","family":"de Wreede","sequence":"first","affiliation":[{"name":"Leiden University Medical Center, Department of Biomedical Data Sciences, Leiden, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9542-3169","authenticated-orcid":false,"given":"Daniel","family":"F\u00fcrst","sequence":"first","affiliation":[{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg\u2013Hessen and University Hospital Ulm, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kobbe","sequence":"first","affiliation":[{"name":"University Hospital D\u00fcsseldorf, Medical Faculty, Heinrich Heine University D\u00fcsseldorf, D\u00fcsseldorf, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hellmut D.","family":"Ottinger","sequence":"first","affiliation":[{"name":"Department of Bone Marrow Transplantation, West German Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich W.","family":"Beelen","sequence":"first","affiliation":[{"name":"Department of Bone Marrow Transplantation, West German Cancer Center, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joannis","family":"Mytilineos","sequence":"first","affiliation":[{"name":"Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg\u2013Hessen and University Hospital Ulm, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5827-8000","authenticated-orcid":false,"given":"Katharina","family":"Fleischhauer","sequence":"first","affiliation":[{"name":"Institute for Experimental Cellular Therapy, University of Duisburg\u2013Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0979-5914","authenticated-orcid":false,"given":"Alexander H.","family":"Schmidt","sequence":"first","affiliation":[{"name":"DKMS gemeinn\u00fctzige GmbH, T\u00fcbingen, Germany;"},{"name":"DKMS Life Science Laboratory, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2020041611581390000_B1","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2020041611581390000_B2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020041611581390000_B3","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2015.12.028","article-title":"Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation","volume":"22","author":"Shaffer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"357","key":"2020041611581390000_B4","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"issue":"8","key":"2020041611581390000_B5","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","article-title":"Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML","volume":"24","author":"Bj\u00f6rklund","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2020041611581390000_B6","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood-2003-01-0091","article-title":"Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors","volume":"102","author":"Giebel","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2020041611581390000_B7","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1182\/blood-2004-12-4825","article-title":"Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes","volume":"105","author":"Hsu","year":"2005","journal-title":"Blood"},{"issue":"11","key":"2020041611581390000_B8","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1182\/blood-2007-01-065383","article-title":"Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT","volume":"109","author":"Miller","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2020041611581390000_B9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"issue":"5562","key":"2020041611581390000_B10","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"3","key":"2020041611581390000_B11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0198-8859(01)00381-0","article-title":"Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon","volume":"63","author":"Brouwer","year":"2002","journal-title":"Hum Immunol"},{"issue":"6","key":"2020041611581390000_B12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00262-008-0601-7","article-title":"Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by natural killer cells","volume":"58","author":"Verheyden","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2020041611581390000_B13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"issue":"6","key":"2020041611581390000_B14","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/ng2035","article-title":"Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1","volume":"39","author":"Martin","year":"2007","journal-title":"Nat Genet"},{"issue":"6128","key":"2020041611581390000_B15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.1232685","article-title":"Influence of HLA-C expression level on HIV control","volume":"340","author":"Apps","year":"2013","journal-title":"Science"},{"issue":"7","key":"2020041611581390000_B16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood-2012-09-455352","article-title":"Inhibitory KIR\/HLA incompatibility between sexual partners confers protection against HIV-1 transmission","volume":"121","author":"Jennes","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2020041611581390000_B17","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.4049\/jimmunol.1502469","article-title":"KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV","volume":"196","author":"Boudreau","year":"2016","journal-title":"J Immunol"},{"issue":"9","key":"2020041611581390000_B18","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1056\/NEJMoa1200503","article-title":"HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1","volume":"367","author":"Venstrom","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"2020041611581390000_B19","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1200\/JCO.2016.70.7059","article-title":"KIR3DL1\/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation","volume":"35","author":"Boudreau","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020041611581390000_B20","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.4049\/jimmunol.166.5.2992","article-title":"Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism","volume":"166","author":"Gardiner","year":"2001","journal-title":"J Immunol"},{"key":"2020041611581390000_B21","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.3389\/fimmu.2018.02843","article-title":"Allele-level KIR genotyping of more than a million samples: workflow, algorithm, and observations","volume":"9","author":"Wagner","year":"2018","journal-title":"Front Immunol"},{"issue":"20","key":"2020041611581390000_B22","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2020041611581390000_B23","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2020041611581390000_B24","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020041611581390000_B25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"6","key":"2020041611581390000_B26","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2009-09-245746","article-title":"Education of human natural killer cells by activating killer cell immunoglobulin-like receptors","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2020041611581390000_B27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jclinepi.2008.12.004","article-title":"Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement","volume":"62","author":"Little","year":"2009","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2020041611581390000_B28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1399-0039.2011.01777.x","article-title":"A community standard for immunogenomic data reporting and analysis: proposal for a STrengthening the REporting of Immunogenomic Studies statement","volume":"78","author":"Hollenbach","year":"2011","journal-title":"Tissue Antigens"},{"issue":"5","key":"2020041611581390000_B29","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2402893","article-title":"Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation?","volume":"17","author":"Heimfeld","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"2020041611581390000_B30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbmt.2009.10.004","article-title":"The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes","volume":"16","author":"Collins","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"2020041611581390000_B31","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1182\/blood-2009-08-236943","article-title":"Donor activating KIR3DS1 is associated with decreased acute GVHD in unrelated allogeneic hematopoietic stem cell transplantation","volume":"115","author":"Venstrom","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2020041611581390000_B32","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.4049\/jimmunol.177.10.6588","article-title":"Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands","volume":"177","author":"Jennes","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"2020041611581390000_B33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2017.03.040","article-title":"HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs","volume":"67","author":"Th\u00f6ns","year":"2017","journal-title":"J Hepatol"},{"issue":"24","key":"2020041611581390000_B34","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"2020041611581390000_B35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"12","key":"2020041611581390000_B36","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1128\/JVI.00412-11","article-title":"Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules","volume":"85","author":"Fadda","year":"2011","journal-title":"J Virol"},{"issue":"4","key":"2020041611581390000_B37","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nsmb.3381","article-title":"MHC-I peptides get out of the groove and enable a novel mechanism of HIV-1 escape","volume":"24","author":"Pymm","year":"2017","journal-title":"Nat Struct Mol Biol"},{"issue":"14","key":"2020041611581390000_B38","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2010-05-283051","article-title":"Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia","volume":"116","author":"Cooley","year":"2010","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/16\/1386\/1724146\/bloodbld2019002887.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/135\/16\/1386\/1724146\/bloodbld2019002887.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T19:10:34Z","timestamp":1587064234000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/135\/16\/1386\/430248\/External-validation-of-models-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":38,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2020,4,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019002887","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]}}}